<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0411200251
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Sildenafil OHRE Pharma
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SILDENAFIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        90
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1327.499
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PHARMACEUTICAL WORKS POLPHARMA S.A." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PHARMACEUTICAL WORKS POLPHARMA S.A.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 461]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            QOMEL MEDICAL DRUG STORE
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            STRAGEN FRANCE
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G04BE03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Sildenafil OHRE Pharma contains the active substance sildenafil which belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors.</p><p dir="ltr">Sildenafil OHRE Pharma brings down blood pressure in the lungs by widening the blood vessels in the lungs.</p><p dir="ltr">Sildenafil OHRE Pharma is used to treat adults and children and adolescents from 1 to 17 years old with high blood pressure in the blood vessels in the lungs (pulmonary arterial hypertension).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">1.&nbsp; Do not take Sildenafil OHRE Pharma:</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to sildenafil or any of the other ingredients of this medicine (listed in section 6).</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking medicines containing nitrates, or nitric oxide donors such as amyl nitrate (&ldquo;poppers&rdquo;). These medicines are often given for relief of chest pain (or &ldquo;angina pectoris&rdquo;). Sildenafil OHRE Pharma can cause a serious increase in the effects of these medicines. Tell your doctor if you are taking any of these medicines. If you are not certain, ask your doctor or pharmacist.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking riociguat. This drug is used to treat pulmonary arterial hypertension (i.e., high blood pressure in the lungs) and chronic thromboembolic pulmonary hypertension (i.e., high blood pressure in the lungs secondary to blood clots). PDE5 inhibitors, such as Sildenafil OHRE Pharma have been shown to increase the hypotensive effects of this medicine. If you are taking riociguat or are unsure tell your doctor.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have recently had a stroke, a heart attack or if you have severe liver disease or very low blood pressure (&lt;90/50 mmHg).</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking a medicine to treat fungal infections such as ketoconazole or itraconazole or medicines containing ritonavir (for HIV).</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had loss of vision because of a problem with blood flow to the nerve in the eye called non-arteritic anterior ischaemic optic neuropathy (NAION).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Warnings and precautions</p><p dir="ltr">Talk to your doctor before taking Sildenafil OHRE Pharma if you:</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a disease due to a blocked or narrow vein in the lungs rather than a blocked or narrow artery.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a severe heart problem.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a problem with the pumping chambers of your heart</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have high blood pressure in the blood vessels in the lungs.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have low blood pressure at rest.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lose a large amount of body fluids (dehydration) which can occur when you sweat a lot or do not drink enough liquids. This can happen if you are sick with a fever, vomiting, or diarrhoea.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a rare inherited eye disease (<em>retinitis pigmentosa</em>).</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have an abnormality of red blood cells (sickle cell anaemia), cancer of blood cells (leukaemia), cancer of bone marrow (multiple myeloma), or any disease or deformity of the penis.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; currently have a stomach ulcer, a bleeding disorder (such as haemophilia) or problems with nose bleeds.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; take medicines for erectile dysfunction.</p><p dir="ltr">&nbsp;</p><p dir="ltr">When used to treat male erectile dysfunction (ED), the following visual side effects have been reported with PDE5 inhibitors, including sildenafil at an unknown frequency; partial, sudden, temporary, or permanent decrease or loss of vision in one or both eyes.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you experience sudden decrease or loss of vision, <strong>stop taking Sildenafil OHRE Pharma and contact your doctor immediately </strong>(see also section 4).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Prolonged and sometimes painful erections have been reported in men after taking sildenafil. If you have an erection, which lasts continuously for more than 4 hours, <strong>stop taking Sildenafil OHRE Pharma and contact your doctor immediately </strong>(see also section 4).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Special considerations for patients with kidney or liver problems</em></p><p dir="ltr">You should tell your doctor if you have kidney or liver problems, as your dose may need to be adjusted.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Children</p><p dir="ltr">Sildenafil OHRE Pharma should not be given to children below 1 year of age.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Other medicines and Sildenafil OHRE Pharma</p><p dir="ltr">Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p dir="ltr"><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1028" type="#_x0000_t75" style='width:8.5pt;
 height:13.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="11" height="18" src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />&nbsp;Medicines containing nitrates, or nitric oxide donors such as amyl nitrate (&ldquo;poppers&rdquo;).</p><p dir="ltr">These medicines are often given for relief of angina pectoris or &ldquo;chest pain&rdquo; (see section 2. Before you take Sildenafil OHRE Pharma)</p><p dir="ltr"><!--[if gte vml 1]><v:group
 id="docshapegroup1" o:spid="_x0000_s1026" style='position:absolute;left:0;
 text-align:left;margin-left:113.4pt;margin-top:.1pt;width:8.3pt;height:41.05pt;
 z-index:15728640;mso-position-horizontal-relative:page' coordorigin="2268,2"
 coordsize="166,821" o:gfxdata="UEsDBBQABgAIAAAAIQA0Ev94FAEAAFACAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSy07DMBBF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">
 <v:shape id="docshape2" o:spid="_x0000_s1027" type="#_x0000_t75" style='position:absolute;
  left:2268;top:1;width:166;height:272;visibility:visible;mso-wrap-style:square'
  o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:imagedata src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
   o:title=""/>
 </v:shape><v:shape id="docshape3" o:spid="_x0000_s1028" type="#_x0000_t75"
  style='position:absolute;left:2268;top:277;width:166;height:545;visibility:visible;
  mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:imagedata src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image004.png"
   o:title=""/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="11" height="55" src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image005.gif" />Tell your doctor or pharmacist if you are already taking riociguat. Therapies for pulmonary hypertension (e.g. bosentan, iloprost)</p><p dir="ltr">Medicines containing St. John&rsquo;s Wort (herbal medicinal product), rifampicin (used to treat bacterial infections), carbamazepine, phenytoin and phenobarbital (used, among others, to treat epilepsy)</p><p dir="ltr"><!--[if gte vml 1]><v:shape
 id="_x0000_i1027" type="#_x0000_t75" style='width:8.5pt;height:13.5pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="11" height="18" src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />&nbsp;Blood thinning medicines (for example warfarin) although these did not result in any side effect.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><!--[if gte vml 1]><v:shape
 id="_x0000_i1026" type="#_x0000_t75" style='width:8.5pt;height:13.5pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="11" height="18" src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />&nbsp;Medicines containing erythromycin, clarithromycin, telithromycin (these are antibiotics used to treat certain bacterial infections), saquinavir (for HIV) or nefazodone (for mental depression), as your dose may need to be adjusted.</p><p dir="ltr"><!--[if gte vml 1]><v:shape
 id="image1.png" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:8.5pt;
 height:13.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="11" height="18" src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />&nbsp;Alpha-blocker therapy (e.g. doxazosin) for the treatment of high blood pressure or prostate problems, as the combination of the two medicines may cause symptoms resulting in the lowering of your blood pressure (e.g. dizziness, light headedness).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Sildenafil OHRE Pharma with food and drink</p><p dir="ltr">You should not drink grapefruit juice while you are being treated with Sildenafil OHRE Pharma.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Pregnancy and breast-feeding</p><p dir="ltr">If you are pregnant, or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Sildenafil OHRE Pharma should not be used during pregnancy unless strictly necessary.</p><p dir="ltr">Sildenafil OHRE Pharma should not be given to women of child bearing potential unless using appropriate contraceptive methods.</p><p dir="ltr">Stop breast-feeding when you start Sildenafil OHRE Pharma treatment. Sildenafil OHRE Pharma should not be given to women who are breast-feeding since it is not known if the medicine passes into the breast milk.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Driving and using machines</p><p dir="ltr">Sildenafil OHRE Pharma can cause dizziness and can affect vision. You should be aware of how you react to the medicine before you drive or use machines.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Sildenafil OHRE Pharma contains lactose</p><p dir="ltr">If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this -medicinal product.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p dir="ltr">For adults, the recommended dose is 20 mg three times a day (taken 6 to 8 hours apart) taken with or without food.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Use in children and adolescents</p><p dir="ltr">For children and adolescents aged 1 year to 17 years old, the recommended dose is either 10 mg (1 ml of an oral suspension) three times a day for children and adolescents &le; 20 kg or 20 mg (1 tablet) three times a day for children and adolescents &gt; 20 kg, taken with or without food. Higher doses should not be used in children.</p><p dir="ltr">As an accurate dosage cannot be achieved with the 20 mg non scored tablet formulation in this patient population, it is recommended to use other available formulations.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you take more Sildenafil OHRE Pharma than you should</p><p dir="ltr">You should not take more medicine than your doctor tells you to.</p><p dir="ltr">If you take more medicine than you have been told to take contact your doctor immediately. Taking more Sildenafil OHRE Pharma than you should may increase the risk of known side effects.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you forget to take Sildenafil OHRE Pharma</p><p dir="ltr">If you forget to take Sildenafil OHRE Pharma, take a dose as soon as you remember, then continue to take your medicine at the usual times. Do not take a double dose to make up for a forgotten dose.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you stop taking Sildenafil OHRE Pharma</p><p dir="ltr">Suddenly stopping your treatment with Sildenafil OHRE Pharma may lead to your symptoms getting worse. Do not stop taking Sildenafil OHRE Pharma unless your doctor tells you to. Your doctor may tell you to reduce the dose over a few days before stopping completely.</p><p dir="ltr">If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, Sildenafil OHRE Pharma can cause side effects, although not everybody gets them. If you experience any of the following side effects, you should stop taking Sildenafil OHRE Pharma and contact a doctor immediately (see also section 2):</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience sudden decrease or loss of vision (frequency not known)</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have an erection, which lasts continuously for more than 4 hours. Prolonged and sometimes painful erections have been reported in men after taking sildenafil (frequency not known).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Adults</u></p><p dir="ltr">Side effects reported very commonly (may affect more than 1 in 10 people) were headache, facial flushing, indigestion, diarrhoea and pain in the arms or legs.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Side effects reported commonly (may affect up to 1 in 10 people) included: infection under the skin, flu- like symptoms, inflammation of the sinuses, reduced number of red blood cells (anaemia), fluid</p><p dir="ltr">retention, difficulty sleeping, anxiety, migraine, shaking, &ldquo;pins and needles&rdquo;-like sensation, burning sensation, reduced sense of touch, bleeding at the back of the eye, effects on vision, blurred vision and light sensitivity, effects on colour vision, eye irritation, bloodshot eyes /red eyes, vertigo, bronchitis, nosebleed, runny nose, cough, stuffy nose, stomach inflammation, gastroenteritis, heartburn, piles, abdominal distension, dry mouth, hair loss, redness of the skin, night sweats, muscle aches, back pain and increased body temperature.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Side effects reported uncommonly (may affect 1 in 100 people) included: reduced sharpness of vision, double vision, abnormal sensation in the eye, penile bleeding, presence of blood in semen and/or urine, and breast enlargement in men.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Skin rash and sudden decrease or loss of hearing and decreased blood pressure have also been reported at an unknown frequency (frequency cannot be estimated from the available data).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Children and adolescents</u></p><p dir="ltr">The following serious adverse events have been reported commonly (may affect up to 1 in 10 people); pneumonia, heart failure, right heart failure, heart related shock, high blood pressure in the lungs, chest pain, fainting, respiratory infection, bronchitis, viral infection in the stomach and intestines, urinary tract infections and tooth cavities.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The following serious adverse events were considered to be treatment related and were reported uncommonly (may affect up to 1 in 100 people), allergic reaction (such as skin rash, swelling of the face, lips and tongue, wheezing, difficulty breathing or swallowing), convulsion, irregular heart-beat, hearing impairment, shortness of breath, inflammation of the digestive tract, wheezing due to disrupted airflow.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Side effects reported very commonly (may affect more than 1 in 10 people) were headache, vomiting, infection of the throat, fever, diarrhoea, flu and nosebleed.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Side effects reported commonly (may affect up to 1 in 10 people) were nausea, increased erections, pneumonia and runny nose.</p><p dir="ltr">&nbsp;</p><p dir="ltr">To report any side effect(s):</p><ul dir="ltr"><li><strong><em>Saudi Arabia: </em></strong></li></ul><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>- The National Pharmacovigilance Centre (NPC)</p><p>o&nbsp;&nbsp; Toll free phone: 19999</p><p>o&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa &nbsp;&nbsp;</p><p>o&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp; Other GCC States:</p><p dir="ltr">&nbsp;</p><p dir="ltr">-&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Keep this medicine out of the sight and reach of children.</p><p dir="ltr">Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.</p><p dir="ltr">This medicinal product does not require any special storage conditions.</p><p dir="ltr">Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">What Sildenafil OHRE Pharma contains</p><p dir="ltr">-&nbsp; The active substance is sildenafil. Each tablet contains 20 mg of sildenafil (as the citrate).</p><p dir="ltr">-&nbsp; The other ingredients are:</p><p dir="ltr">Tablet core: Mannitol, Crospovidone- type A , Povidone- K-30, Maize starch, Sodium laurilsulfate, anhydrous colloidal Silica, Magnesium stearate.</p><p dir="ltr">Film coat: Hypromellose, Titanium dioxide (E171), Lactose monohydrate, Macrogol, Triacetin</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Sildenafil OHRE Pharma film-coated tablets are white, biconvex, round film-coated tablet of 5 mm diameter.
The tablets are provided in Al/PVC/PVDC blister packs containing 90 tablets
and in Al/PVC/PVDC blister packs containing 300 tablets. Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Marketing Authorisation Holder and Manufacturer</p><p dir="ltr">Marketing Authorisation Holder:</p><p dir="ltr">STRAGEN FRANCE30 rue Edouard Nieuport</p><p dir="ltr">69008 Lyon</p><p dir="ltr">France</p><p dir="ltr">&nbsp;</p><p dir="ltr">Manufacturer:</p><p dir="ltr"><strong>Pharmaceutical Works Polpharma S.A.</strong></p><p dir="ltr">19 Pelplinska Str.</p><p dir="ltr">83-200 Starogard Gdanski&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp;&nbsp; Poland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 01/10/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>تحتوي أقراص سلدنافيل أوري فارما على المادة الفعالة &quot;سلدنافيل&quot; التي تنتمي إلى مجموعة من الأدوية تسمى مثبطات انزيم فوسفو ثنائي استريز نوع-5 (PDE5).</p><p>يقوم سلدنافيل أوري فارما بخفض ضغط الدم في الرئتين من خلال توسعة الأوعية الدموية داخل الرئتين.</p><p>يستعمل سلدنافيل أوري فارما لعلاج البالغين والأطفال والمراهقين في مرحلة العمر 1-17 سنة الذين يعانون من ارتفاع ضغط الدم في الأوعية الدموية بالرئتين (ارتفاع ضغط الدم الشرياني الرئوي).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول سلدنافيل أوري فارما في الحالات التالية</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية لـ &quot;سلدنافيل&quot; أو لأي من مكونات هذا الدواء الأخرى (المدرجة في الفقرة رقم-6).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; إذا كنت تستعمل أدوية تحتوي على النيترات او التي تطلق اكسيد النيتريك في الجسم مثل نيترات الأميل (&quot;المفتقات&quot;). وهذه الأدوية تعطى عادة لتخفيف ألم الصدر (او الذبحة الصدرية).</p><p dir="RTL">سلدنافيل أوري فارما يمكن ان يسبب زيادة خطيرة في مفعول هذه الأدوية. يجب استشارة الطبيب قبل البدء في استعمال تلك الأدوية وإذا كنت غير متأكد من مكونات أي ادوية تستعملها عليك أن تسأل الطبيب او الصيدلي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; إذا كنت تستعمل ريوسيجوات. هذا الدواء يستعمل لعلاج ارتفاع ضغط الدم الشرياني الرئوي (أي ارتفاع ضغط الدم بالرئتين) وارتفاع ضغط الدم الرئوي المزمن المرتبط بالجلطة الرئوية. (أي ارتفاع ضغط الدم داخل الرئتين نتيجة جلطات دموية بالرئتين).</p><p dir="RTL">وقد ثبت أن مثبطات انزيم فوسفو ثنائي استريز نوع-5 (PDE5) مثل سلدنافيل أوري فارما تؤدي إلى زيادة مفعول هذا الدواء (ريوسيجوات) الخافض لضغط الدم.</p><p dir="RTL">إذا كنت تستعمل ريوسيجوات او كنت غير متأكد عليك استشارة الطبيب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; إذا كنت قد اصبت حديثًا بجلطة في الدماغ (سكتة دماغية)، أو نوبة قلبية أو إذا كنت تعاني من مرض شديد بالكبد او تعاني من انخفاض شديد في ضغط الدم (&lt; 90/50 ملم زئبق).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; إذا كنت تستعمل دواء لعلاج الإصابة بالفطريات مثل كيتوكونازول او ايتراكونازول او أدوية تحتوي على ريتونافير (لعلاج فيروس نقص المناعة البشري).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; إذا كنت قد اصبت بفقدان الرؤية بسبب مشكلة في تدفق الدم الى عصب بالعين وهي حالة تسمى الاعتلال العصبي البصري الإحتشائي الأمامي غير الشرياني (NAION).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي من الحالات المذكورة اعلاه يجب عليك ابلاغ الطبيب.</p><p dir="RTL">&nbsp;</p><p>تحذيرات واحتياطات</p><p dir="RTL">عليك التحدث إلى الطبيب قبل البدء في استعمال سلدنافيل أوري فارما إذا كانت لديك أي من الحالات التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض ناتج عن انسداد او ضيق في وريد رئوي وليس في شريان رئوي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلة شديدة بالقلب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلة في ضخ الدم من حجرات القلب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع في ضغط الدم في الأوعية الدموية بالرئتين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في ضغط الدم عندما تكون في وضعية الراحة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان كميات كبيرة من سوائل الجسم (جفاف) والذي يمكن ان يحدث عند التعرق الغزير او عند عدم شرب كميات كافية من السوائل. وقد يحدث ذلك إذا كنت مصابا بالحمى او التقيؤ أو الإسهال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصابة بمرض وراثي نادر في العينين (التهاب الشبكية التصبغي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل او عيوب في كريات الدم الحمراء (انيميا الخلايا المنجلية)، او سرطان في الخلايا الدموية (ابيضاض الدم &quot;اللوكيميا&quot;)، او سرطان في نخاع العظام (ورم الميلوما المتعدد)، أو أي مرض او تشوه في القضيب (العضو الذكري).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرحة في المعدة في الوقت الراهن، أو خلل نزفي دموي (مثل مرض الناعور &quot;الهيموفيليا&quot;)، أو مشاكل نزيف متكرر من الأنف.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستعمل أدوية لعلاج خلل الانتصاب.</p><p dir="RTL">عند استعمال مثبطات انزيم فوسفو ثنائي استريز نوع-5 (PDE5) بما فيها سلدنافيل لعلاج خلل الانتصاب, تم الإبلاغ عن التأثيرات الجانبية التالية في النظر بمعدلات ووتيرة غير معروفة: نقص جزئي فجائي مؤقت او دائم في قدرة الإبصار أو فقدان النظر في احدى العينين او كليهما.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا حدث لديك نقص فجائي في قدرة الإبصار أو فقدان النظر <strong>يجب عليك التوقف عن تناول سلدنافيل أوري فارما والاتصال بالطبيب على الفور</strong>، (انظر ايضا الفقرة رقم-4).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تم الإبلاغ عن حالات انتصاب متواصل -ومؤلم أحيانا- لدى الرجال بعد تناول سلدنافيل. فإذا حدث لديك انتصاب واستمر بصورة متواصلة لمدة تزيد عن 4 ساعات <strong>يجب عليك التوقف عن تناول سلدنافيل أوري فارما والاتصال بالطبيب على الفور</strong> (انظر ايضا الفقرة رقم-4).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>اعتبارات خاصة بالنسبة للمرضى الذين يعانون من مشاكل في الكلى أو الكبد</em></p><p dir="RTL">يجب عليك ابلاغ الطبيب إذا كانت تعاني من أي مشاكل في الكلى أو الكبد حيث انه قد يلزم تعديل جرعاتك من هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">يجب عدم إعطاء سلدنافيل أوري فارما للأطفال الذين تقل اعمارهم عن سنة واحدة.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وسلدنافيل أوري فارما</strong></p><p dir="RTL">يرجى استشارة الطبيب أو الصيدلي إذا كنت تستعمل او استعملت حديثًا او يتوقع ان تستخدم أي أدوية أخرى.</p><ul><li dir="RTL">الأدوية التي تحتوي على النيترات او التي تطلق اكسيد النيتريك في الجسم مثل نيترات الأميل (&quot;المفتقات&quot;). وهذه الأدوية تعطى عادة لتخفيف ألم الصدر (او الذبحة الصدرية). &nbsp;(انظر الفقرة رقم-2 قبل البدء في استعمال سلدنافيل أوري فارما).</li><li dir="RTL">ابلغ الطبيب او الصيدلي إذا كنت تستعمل ريوسيجوات.</li><li dir="RTL">علاجات لارتفاع ضغط الدم الرئوي (مثل بوسنتان، ايلوبروست).</li><li dir="RTL">الأدوية التي تحتوي على عشبة سانت جونز وورث (منتج دوائي عشبي)، او ريفامبيسين (يستعمل لعلاج الإصابات البكتيرية)، او كاربامازيبين، او فينيتوين وفينوباربيتال (التي تستعمل من بين ادوية اخرى لعلاج تشنجات الصرع).</li><li dir="RTL">الأدوية التي تخفف من لزوجة الدم أو تزيد سيولة الدم (مثل الوارفرين) مع انها لا تؤدي إلى أي تأثيرات جانبية.</li><li dir="RTL">&nbsp;الأدوية التي تحتوي على اريثرومايسين، او كلاريثرومايسن، أو تيليثرومايسين (وهي مضادات حيوية تستعمل لعلاج بعض الإصابات البكتيرية)، او ساكوينافير (لعلاج فيروس نقص المناعة البشرية) أو نيفازودون (يستعمل لعلاج الاكتئاب النفسي)؛ حيث انه قد يلزم تعديل جرعاتك.</li><li dir="RTL">علاجات تعطيل مستقبلات الفا (مثل دوكسازوسين) المستخدمة لعلاج ارتفاع ضغط الدم او مشاكل البروستات, حيث الجمع بين هذين الدوائين يمكن ان يسبب اعراض انخفاض ضغط الدم (مثل الدوخة والدوار).</li></ul><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>سلدنافيل أوري فارما مع الطعام والشراب</strong></p><p dir="RTL">يجب عدم شرب عصير الجريب فروت خلال فترة استعمال علاج سلدنافيل أوري فارما.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">يجب على المرأة الحامل أو التي ترضع او التي تعتقد انها حامل او تخطط للحمل, استشارة الطبيب او الصيدلي قبل البدء باستعمال هذا الدواء. يجب عدم استعمال سلدنافيل أوري فارما اثناء الحمل إلا إذا كان ذلك للضرورة القصوى.</p><p dir="RTL">يجب عدم اعطاء سلدنافيل أوري فارما للنساء اللاتي لديهن احتمال الحمل إلا إذا استعملن وسائل فعالة لمنع الحمل. يجب التوقف عن الإرضاع الطبيعيي عند البدء باستعمال سلدنافيل أوري فارما. يجب عدم اعطاء سلدنافيل أوري فارما للنساء المرضعات حيث انه لا يعرف ما إذا كان هذا الدواء يفرز في حليب الثدي أم لا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>قيادة المركبات وتشغيل الآليات</strong></p><p dir="RTL">سلدنافيل أوري فارما يمكن ان يسبب الدوار ويمكن ان يؤثر في الرؤية (النظر). يجب عليك ان تكون على معرفة بكيفية تأثير هذا الدواء عليك قبل ان تباشر في قيادة المركبات أو تشغيل الآليات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>سلدنافيل أوري فارما يحتوي على لاكتوز</strong></p><p dir="RTL">إذا تم ابلاغك بأنك تعاني من مشكلة عدم تقبل بعض أنواع السكر, يجب عليك استشارة الطبيب قبل البدء في استعمال هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب دائما استعمال هذا الدواء حسب تعليمات الطبيب تماماً، وإذا كنت غير متأكد فيجب عليك الإتصال بالطبيب أو الصيدلي.</p><p dir="RTL">بالنسبة للبالغين: الجرعة الموصى بها 20 مجم 3 مرات يومياً (تؤخذ في اوقات تفصل بينها 6-8 ساعات)، ويمكن تناوله مع الطعام أو بدونه.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><strong>الاستعمال لدى الأطفال والمراهقين</strong></p><p dir="RTL">بالنسبة للأطفال والمراهقين في مرحلة العمر 1 &ndash; 17 سنة, الجرعة الموصى بها هي إما 10مجم (1 مل من المحلول الذي يؤخذ بالفم) 3 مرات يومياً للأطفال والمراهقين الذين اوزانهم &le;20 كغ (تقل عن أو تصل لغاية 20 كغ), أو 20 مجم (قرص واحد) 3 مرات يومياً للأطفال والمراهقين الذين اوزانهم &ge;20كغ (تبلغ أو تزيد عن 20 كغ)، تؤخذ مع الطعام أو بدونه. يجب عدم استعمال جرعات أعلى للأطفال.</p><p dir="RTL">وحيث أنه لا يمكن تحقيق جرعة محددة بدقة باستعمال اقراص 20 مجم غير مقسومة بحز لدى هذه الفئة من المرضى, فإننا نوصي باستعمال تركيبات أو أشكال أخرى من هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا تناولت جرعة زائدة من سلدنافيل أوري فارما</strong></p><p dir="RTL">يجب ألّا تتناول من هذا الدواء زيادة عن الجرعات التي وصفها لك الطبيب.</p><p dir="RTL">إذا تناولت من هذا الدواء زيادة عن وصفة الطبيب فيجب عليك الاتصال بالطبيب فوراً. فإن تناول جرعة زائدة من سلدنافيل أوري فارما يمكن ان يزيد من مخاطر حدوث التأثيرات الجانبية المعروفة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا نسيت أن تتناول سلدنافيل أوري فارما</strong></p><p dir="RTL">إذا نسيت ان تتناول الجرعة المعتادة في وقتها فيجب عليك ان تأخذ تلك الجرعة المنسية عندما تتذكرها فوراً ثم عليك مواصلة تناول الجرعات في أوقاتها المعتادة. لا تأخذ جرعة مضاعفة لتعوض تلك التي نسيتها.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا توقفت عن استعمال سلدنافيل أوري فارما</strong></p><p dir="RTL">إنّ التوقف المفاجئ عن استعمال سلدنافيل أوري فارما قد يؤدي إلى تفاقم الأعراض. يجب ألّا تتوقف عن استعمال هذا الدواء إلا إذا نصحك الطبيب بذلك. وقد ينصحك الطبيب بخفض الجرعة لبضعة أيام قبل التوقف عن تناول الدواء نهائياً.</p><p dir="RTL">إذا كانت لديك أي أسئلة او استفسارات حول استعمال هذا الدواء فيجب عليك استشارة الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>هذا الدواء كغيره من الأدوية يمكن أن يسبب بعض الآثار الجانبية مع انها لا تحدث لدى جميع الأشخاص.</p><p>إذا حدثت لك أي من التأثيرات الجانبية التالية عليك التوقف عن استعمال سلدنافيل أوري فارما والاتصال بالطبيب فوراً (انظر الفقرة رقم-2):</p><p dir="RTL">&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لاحظت فجأة حدوث نقص او فقدان البصر (معدل الحدوث غير معروف).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا حدث لديك انتصاب متواصل واستمر لمدة تزيد عن 4 ساعات. وقد تم الإبلاغ عن حالات انتصاب متواصل ومؤلم احياناً لدى الرجال بعد تناول سلدنافيل (معدل الحدوث غير معروف).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><u>البالغون</u></p><p>التأثيرات الجانبية الشائعة جدًا (تحدث لدى ما يزيد عن 1 من بين كل 10 اشخاص)</p><p>الصداع، احمرار الوجه، عسر الهضم، الإسهال، الم في الذراعين او الرجلين.</p><p>&nbsp;</p><p>التأثيرات الجانبية الشائعة (يمكن ان تصيب لغاية 1 من بين كل 10 شخص)</p><p>اصابات (عدوى) تحت الجلد، أعراض تشبه أعراض الإنفلونزا، التهاب الجيوب الأنفية، انخفاض في تعداد كريات الدم الحمراء (فقر الدم &quot;انيميا&quot;)، احتباس السوائل، صعوبات في النوم، قلق، صداع نصفي (شقيقة)، ارتعاش، احساس بوخز مثل وخز الإبر، احساس بالحرقان، انخفاض حاسة اللمس، نزيف خلف العينين، تأثيرات على الرؤية، ضبابية الرؤيا وحساسية للضوء، تأثيرات على رؤية الألوان، تهيج العين، احمرار العينين، خلل التوازن (ترنح) ، التهاب القصبات الهوائية، نزيف من الأنف، سيلان الأنف (رشح)، سعال، انسداد الأنف، التهاب المعدة، التهاب المعدة والأمعاء، حرقة، بواسير، انتفاخ البطن، جفاف الفم، تساقط الشعر، احمرار الجلد، نوبات تعرق ليلي، آلام بالعضلات، ألم بالظهر، ارتفاع في درجة حرارة الجسم.</p><p>&nbsp;</p><p>تأثيرات غير شائعة (يمكن ان تصيب لغاية 1 من بين كل 100 شخص)</p><p>انخفاض حدة البصر، ازدواجية الرؤيا، احساس غير طبيعي في العينين، نزيف من القضيب، وجود دم في السائل المنوي و/أو البول، تضخم الثديين لدى الرجال.</p><p>&nbsp;</p><p>وقد تم الإبلاغ عن تأثيرات جانبية اخرى (لا يمكن تحديد معدلات حدوثها من واقع البيانات المتوفرة) وتشمل الطفح الجلدي، نقص او فقدان فجائي للسمع، انخفاض ضغط الدم.</p><p><u>&nbsp;</u></p><p><u>الأطفال والمراهقون</u></p><p>تم الإبلاغ عن التأثيرات الجانبية الخطيرة التالية:</p><p>التأثيرات الجانبية الشائعة (يمكن ان تصيب لغاية 1 من بين كل 10 أشخاص)</p><p>التهاب رئوي، فشل القلب، فشل الجزء الأيمن من القلب، صدمة ذات علاقة بالقلب، ارتفاع ضغط الدم في الرئتين، ألم في الصدر، إغماء، عدوى التهابات الجهاز التنفسي، التهاب الشعب الهوائية، عدوى فيروسية في المعدة والأمعاء، التهابات المسالك البولية، تجويف الأسنان.</p><p>&nbsp;</p><p>تم الإبلاغ عن التأثيرات الجانبية الخطيرة التالية التي اعتبرت مرتبطة باستعمال هذا الدواء:</p><p>تأثيرات غير شائعة (يمكن ان تصيب لغاية 1 من بين كل 100 شخص)</p><p>ردود فعل تحسسية (مثل الطفح الجلدي، تورم الوجه والشفتين واللسان، أزيز تنفسي، صعوبة في التنفس او البلع)، تشنج، عدم انتظام نبض القلب، قصور في السمع، ضيق بالتنفس، التهاب الجهاز الهضمي، أزيز تنفسي ناتج عن خلل في تدفق الهواء.</p><p>&nbsp;</p><p>تأثيرات جانبية شائعة جداً (يمكن ان تصيب أكثر من 1 من بين كل 10 أشخاص)</p><p dir="RTL">صداع<strong>،</strong> قيء<strong>،</strong> التهاب الحلق<strong>،</strong> حمى<strong>،</strong> إسهال<strong>، </strong>إنفلونزا<strong>، </strong>نزيف الأنف.</p><p dir="RTL">&nbsp;</p><p>تأثيرات جانبية شائعة اخرى (يمكن ان تصيب لغاية 1 من بين كل 10 أشخاص)</p><p>غثيان، زيادة حالات الانتصاب، التهاب رئوي، سيلان الأنف.</p><p>&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن أي أثر (آثار) جانبية او اية مشكلات تتعلق بالجودة:</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكه العربيه السعوديه</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المركز الوطني للتيقظ والسلامة الدوائية:</strong></p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الرقم المجاني : </strong><strong>19999</strong></p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>البريد الإلكتروني: </strong><strong>npc.drug@sfda.gov.sa</strong></p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الموقع الإلكتروني: </strong><strong>https://ade.sfda.gov.sa/</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p></td></tr></tbody></table><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول مجلس التعاون الخليجي الاخرى</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>يرجى الاتصال بالجهة المختصة ذات الصله</strong></p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا تستعمل هذا الدواء بعد تاريخ انتهائه المطبوع على العلبة بعد الحروف الإنجليزية: &quot;EXP&quot;.</p><p dir="RTL">يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p dir="RTL">يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">لا تلقي بأي أدوية في شبكة الصرف الصحي او النفايات المنزلية. اسأل الصيدلي عن الطرق السليمة للتخلص من الأدوية التي لم تعد بحاجة لاستخدامها فهذه الإجراءات تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا يحتوي سلدنافيل أوري فارما</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي &quot;سلدنافيل&quot; يحتوي كل قرص على 20 ملغ من السلدنافيل (على هيئة ملح سترات).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL"><u>مكونات في كتلة القرص:</u> مانيتول، كروسبوفيدون نوع-أي، بوفيدون-كي-30، نشاء الذرة، لوريل سلفات الصوديوم، سيليكا غروية لامائية، ستيارات المغنيسيوم.</p><p dir="RTL"><u>مكونات في غلاف القرص</u>: هايبروميلوز، ثاني اكسيد التيتانيوم (إي-171)، لاكتوز احادي مائي، ماكروجول، ثلاثي اسيتين.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص سلدنافيل أوري فارما المغلفة بالفيلم هي أقراص مستديرة, محدبة من الجانبين, بيضاء اللون, بقطر 5 مم. &nbsp;</p><p dir="RTL">تقدم الأقراص في شرائط بثورية من مادة (AL/PVC/PVDC) بداخل عبوات تحتوي كل منها على 90 قرص مغلف.</p><p dir="RTL">وفي شرائط بثورية من مادة (AL/PVC/PVDC) بداخل عبوات تحتوي كل منها على 300 قرص مغلف.</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل ترخيص التسويق والشركة المصنعة</strong></p><p dir="RTL"><strong>حامل ترخيص التسويق:</strong></p><p dir="RTL"><strong>ستراجن</strong>[u1]&nbsp;<strong> فرنسا</strong></p><p dir="RTL">30 شارع ادوارد نيوبورت</p><p dir="RTL">69008 ليون- فرنسا&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة:</strong></p><p dir="RTL">&nbsp;٥٩١٢١&nbsp;</p><p dir="RTL"><strong>فارماسوتيكالز ووركس بولفارما اس ايه</strong> (بولفارما للأعمال الدوائية)</p><p dir="RTL">19 شارع بيبلنسكا</p><p dir="RTL">200-83 ستارجارد جادنسكي &ndash; بولندا</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            01 اكتوبر 2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sildenafil OHRE Pharma 20 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 20 mg of sildenafil (as citrate).
Excipient(s) with known effect
Each tablet also contains 0.4 mg of lactose.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
White, biconvex, round film-coated tablet of 5 mm diameter.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Adults</u></p><p dir="ltr">Treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease.</p><p dir="ltr"><u>Pediatric population</u></p><p dir="ltr">Treatment of pediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease (see section 5.1).</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Treatment should only be initiated and monitored by a physician experienced in the treatment of pulmonary arterial hypertension. In case of clinical deterioration in spite of Sildenafil OHRE Pharma treatment, alternative therapies should be considered.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Posology</u></p><p dir="ltr"><em><u>Adults</u></em></p><p dir="ltr">The recommended dose is 20 mg three times a day (TID). Physicians should advise patients who forget to take Sildenafil OHRE Pharma to take a dose as soon as possible and then continue with the normal dose.</p><p dir="ltr">Patients should not take a double dose to compensate for the missed dose.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Paediatric population (1 year to 17 years)</u></em></p><p dir="ltr">For paediatric patients aged 1 year to 17 years old, the recommended dose in patients</p><p dir="ltr">&le; 20 kg is 10 mg three times a day and for patients &gt; 20 kg is 20 mg three times a day. Higher than recommended doses should not be used in paediatric patients with PAH (see also sections 4.4 and 5.1).</p><p dir="ltr">As an accurate dosage cannot be achieved with the 20 mg non scored tablet formulation in this patient population, it is recommended to use other available formulations.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Patients using other medicinal products</u></em></p><p dir="ltr">In general, any dose adjustment should be administered only after a careful benefit- risk assessment. A downward dose adjustment to 20 mg twice daily should be considered when sildenafil is coadministered to patients already receiving CYP3A4 inhibitors like erythromycin or saquinavir. A downward dose adjustment to 20 mg once daily is recommended in case of co-administration with more potent CYP3A4 inhibitors clarithromycin, telithromycin and nefazodone. For the use of sildenafil with the most potent CYP3A4 inhibitors, see section 4.3. Dose adjustments for sildenafil may be required when co-administered with CYP3A4 inducers (see section 4.5).</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Special populations</u></em></p><p dir="ltr"><em><u>Elderly (&ge; 65 years)</u></em></p><p dir="ltr">&nbsp;</p><p dir="ltr">Dose adjustments are not required in elderly patients. Clinical efficacy as measured by 6-minute walk distance could be less in elderly patients.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Renal impairment</u></em></p><p dir="ltr">Initial dose adjustments are not required in patients with renal impairment, including severe renal impairment (creatinine clearance &lt; 30 ml/min<em>). </em>A downward dose adjustment to 20 mg twice daily should be considered after a careful benefit-risk assessment only if therapy is not well-tolerated.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Hepatic impairment</u></em></p><p dir="ltr">Initial dose adjustments are not required in patients with hepatic impairment (Child- Pugh class A and B). A downward dose adjustment to 20 mg twice daily should be considered after a careful benefit-risk assessment only if therapy is not well-tolerated. Sildenafil OHRE Pharma is contraindicated in patients with severe hepatic impairment (Child-Pugh class C) (see section 4.3).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Pediatric population</u></em></p><p dir="ltr">The safety and efficacy of Sildenafil OHRE Pharma in children below 1 year of age has not been established. No data are available.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Discontinuation of treatment</u></p><p dir="ltr">Limited data suggests that the abrupt discontinuation of Sildenafil OHRE Pharma is not associated with rebound worsening of pulmonary arterial hypertension. However to avoid the possible occurrence of sudden clinical deterioration during withdrawal, a gradual dose reduction should be considered. Intensified monitoring is recommended during the discontinuation period.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Method of administration</u></p><p dir="ltr">Sildenafil OHRE Pharma is for oral use only. Tablets should be taken approximately 6 to 8 hours apart with or without food.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Co-administration with nitric oxide donors (such as amyl nitrite) or nitrates in any form due to the hypotensive effects of nitrates (see section 5.1).

The co-administration of PDE5 inhibitors, including sildenafil, with guanylate cyclase stimulators, such as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see section 4.5).

Combination with the most potent of the CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir) (see section 4.5).

Patients who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure (see section 4.4).

The safety of sildenafil has not been studied in the following sub-groups of patients and its use is therefore contraindicated: Severe hepatic impairment, Recent history of stroke or myocardial infarction,
Severe hypotension (blood pressure < 90/50 mmHg) at initiation.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">The efficacy of Sildenafil OHRE Pharma has not been established in patients with severe pulmonary arterial hypertension (functional class IV). If the clinical situation deteriorates, therapies that are recommended at the severe stage of the disease (eg, epoprostenol) should be considered (see section 4.2). The benefit-risk balance of sildenafil has not been established in patients assessed to be at WHO functional class I pulmonary arterial hypertension.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Studies with sildenafil have been performed in forms of pulmonary arterial hypertension related to primary (idiopathic), connective tissue disease associated or congenital heart disease associated forms of PAH (see section 5.1). The use of sildenafil in other forms of PAH is not recommended.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In the long term paediatric extension study, an increase in deaths was observed in patients administered doses higher than the recommended dose. Therefore, doses higher than the recommended doses should not be used in paediatric patients with PAH (see also sections 4.2 and 5.1).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Retinitis pigmentosa</u></p><p dir="ltr">The safety of sildenafil has not been studied in patients with known hereditary degenerative retinal disorders such as <em>retinitis pigmentosa </em>(a minority of these patients have genetic disorders of retinal phosphodiesterases) and therefore its use is not recommended.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Vasodilatory action</u></p><p dir="ltr">When prescribing sildenafil, physicians should carefully consider whether patients with certain underlying conditions could be adversely affected by sildenafil&rsquo;s mild to</p><p dir="ltr">moderate vasodilatory effects, for example patients with hypotension, patients with fluid depletion, severe left ventricular outflow obstruction or autonomic dysfunction (see section 4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Cardiovascular risk factors</u></p><p dir="ltr">In post-marketing experience with sildenafil for male erectile dysfunction, serious cardiovascular events, including myocardial infarction, unstable angina, sudden cardiac death, ventricular arrhythmia, cerebrovascular haemorrhage, transient ischaemic attack, hypertension and hypotension have been reported in temporal association with the use of sildenafil. Most, but not all, of these patients had preexisting cardiovascular risk factors. Many events were reported to occur during or shortly after sexual intercourse and a few were reported to occur shortly after the use of sildenafil without sexual activity. It is not possible to determine whether these events are related directly to these factors or to other factors.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Priapism</u></p><p dir="ltr">Sildenafil should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie&rsquo;s disease), or in patients who have conditions which may predispose them to priapism (such as sickle cell anaemia, multiple myeloma or leukaemia).</p><p dir="ltr">Prolonged erections and priapism have been reported with sildenafil in post- marketing experience. In the event of an erection that persists longer than 4 hours, the patient should seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency could result (see section 4.8).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Vaso-occlusive crises in patients with sickle cell anaemia</u></p><p dir="ltr">Sildenafil should not be used in patients with pulmonary hypertension secondary to sickle cell anaemia. In a clinical study events of vaso-occlusive crises requiring hospitalisation were reported more commonly by patients receiving Sildenafil OHRE Pharma than those receiving placebo leading to the premature termination of this study.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Visual events</u></p><p dir="ltr">Cases of visual defects have been reported spontaneously in connection with the intake of sildenafil and other PDE5 inhibitors. Cases of non-arteritic anterior ischaemic optic neuropathy, a rare condition, have been reported spontaneously and in an observational study in connection with the intake of sildenafil and other PDE5 inhibitors (see section 4.8). In the event of any sudden visual defect, the treatment should be stopped immediately and alternative treatment should be considered (see section 4.3).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Alpha-blockers</u></p><p dir="ltr">Caution is advised when sildenafil is administered to patients taking an alpha-blocker as the coadministration may lead to symptomatic hypotension in susceptible individuals (see section 4.5). In order to minimise the potential for developing postural hypotension, patients should be haemodynamically stable on alpha-blocker therapy</p><p dir="ltr">&nbsp;</p><p dir="ltr">prior to initiating sildenafil treatment. Physicians should advise patients what to do in the event of postural hypotensive symptoms.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Bleeding disorders</u></p><p dir="ltr">Studies with human platelets indicate that sildenafil potentiates the antiaggregatory effect of sodium nitroprusside <em>in vitro</em>. There is no safety information on the administration of sildenafil to patients with bleeding disorders or active peptic ulceration. Therefore sildenafil should be administered to these patients only after careful benefit-risk assessment.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Vitamin K antagonists</u></p><p dir="ltr">In pulmonary arterial hypertension patients, there may be a potential for increased risk of bleeding when sildenafil is initiated in patients already using a Vitamin K antagonist, particularly in patients with pulmonary arterial hypertension secondary to connective tissue disease.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Veno-occlusive disease</u></p><p dir="ltr">No data are available with sildenafil in patients with pulmonary hypertension associated with pulmonary veno-occlusive disease. However, cases of life threatening pulmonary oedema have been reported with vasodilators (mainly prostacyclin) when used in those patients. Consequently, should signs of pulmonary oedema occur when sildenafil is administered in patients with pulmonary hypertension, the possibility of associated veno-occlusive disease should be considered.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Galactose intolerance</p><p dir="ltr">Lactose monohydrate is present in the tablet film coat. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Use of sildenafil with bosentan</u></p><p dir="ltr">The efficacy of sildenafil in patients already on bosentan therapy has not been conclusively demonstrated (see sections 4.5 and 5.1).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Concomitant use with other PDE5 inhibitors</u></p><p dir="ltr">The safety and efficacy of sildenafil when co-administered with other PDE5 inhibitor products, including Viagra, has not been studied in PAH patients and such concomitant use is not recommended (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Effects of other medicinal products on sildenafil<br />In vitro studies<br />Sildenafil metabolism is principally mediated by the cytochrome P450 (CYP) isoforms 3A4 (major route) and 2C9 (minor route). Therefore, inhibitors of these isoenzymes may reduce sildenafil clearance and inducers of these isoenzymes may increase sildenafil clearance. For dose recommendations, see sections 4.2 and 4.3.<br />In vivo studies<br />Co-administration of oral sildenafil and intravenous epoprostenol has been evaluated (see sections 4.8 and 5.1).<br />The efficacy and safety of sildenafil co-administered with other treatments for pulmonary arterial hypertension (eg, ambrisentan, iloprost) has not been studied in controlled clinical trials. Therefore, caution is recommended in case of co-administration.<br />The safety and efficacy of sildenafil when co-administered with other PDE5 inhibitors has not been studied in pulmonary arterial hypertension patients (see section 4.4).<br />Population pharmacokinetic analysis of pulmonary arterial hypertension clinical trial data indicated a reduction in sildenafil clearance and/or an increase of oral bioavailability when co-administered with CYP3A4 substrates and the combination of CYP3A4 substrates and beta-blockers. These were the only factors with a statistically significant impact on sildenafil pharmacokinetics in patients with pulmonary arterial hypertension. The exposure to sildenafil in patients on CYP3A4 substrates and<br />CYP3A4 substrates plus beta-blockers was 43 % and 66 % higher, respectively, compared to patients not receiving these classes of medicines. Sildenafil exposure was 5-fold higher at a dose of 80 mg three times a day compared to the exposure at a dose of 20 mg three times a day. This concentration range covers the increase in sildenafil exposure observed in specifically designed drug interaction studies with CYP3A4 inhibitors (except with the most potent of the CYP3A4 inhibitors eg, ketoconazole, itraconazole, ritonavir).<br />CYP3A4 inducers seemed to have a substantial impact on the pharmacokinetics of sildenafil in pulmonary arterial hypertension patients, which was confirmed in the in-vivo interaction study with CYP3A4 inducer bosentan.<br />Co-administration of bosentan (a moderate inducer of CYP3A4, CYP2C9 and possibly of CYP2C19)&nbsp;125 mg twice daily with sildenafil 80 mg three times a day (at steady state) concomitantly administered during 6 days in healthy volunteers resulted in a 63 % decrease of sildenafil AUC. A population pharmacokinetic analysis of sildenafil data from adult PAH patients in clinical trials including a 12 week study to assess the efficacy and safety of oral sildenafil 20 mg three times a day when added to a stable dose of bosentan (62.5 mg &ndash; 125 mg twice a day) indicated a decrease in sildenafil exposure with bosentan co-administration, similar to that observed in healthy volunteers (see sections 4.4 and 5.1).<br />Efficacy of sildenafil should be closely monitored in patients using concomitant potent CYP3A4 inducers, such as carbamazepine, phenytoin, phenobarbital, St John&rsquo;s wort and rifampicine.<br />Co-administration of the HIV protease inhibitor ritonavir, which is a highly potent P450 inhibitor, at steady state (500 mg twice daily) with sildenafil (100 mg single dose) resulted in a 300 % (4-fold) increase in sildenafil Cmax and a 1,000 % (11-fold) increase in sildenafil plasma AUC. At 24 hours, the plasma levels of sildenafil were still approximately 200 ng/ml, compared to approximately 5 ng/ml when sildenafil was administered alone. This is consistent with ritonavir&rsquo;s marked effects on a broad range of P450 substrates. Based on these pharmacokinetic results co-administration of sildenafil with ritonavir is contraindicated in pulmonary arterial hypertension patients (see section 4.3).<br />Co-administration of the HIV protease inhibitor saquinavir, a CYP3A4 inhibitor, at steady state<br />(1200 mg three times a day) with sildenafil (100 mg single dose) resulted in a 140 % increase in sildenafil Cmax and a 210 % increase in sildenafil AUC. Sildenafil had no effect on saquinavir pharmacokinetics. For dose recommendations, see section 4.2.<br />When a single 100 mg dose of sildenafil was administered with erythromycin, a moderate CYP3A4 inhibitor, at steady state (500 mg twice daily for 5 days), there was a 182 % increase in sildenafil systemic exposure (AUC). For dose recommendations, see section 4.2. In healthy male volunteers, there was no evidence of an effect of azithromycin (500 mg daily for 3 days) on the AUC, Cmax, Tmax, elimination rate constant, or subsequent half-life of sildenafil or its principal circulating metabolite.<br />No dose adjustment is required. Cimetidine (800 mg), a cytochrome P450 inhibitor and a non-specific<br />CYP3A4 inhibitor, caused a 56 % increase in plasma sildenafil concentrations when co-administered<br />with sildenafil (50 mg) to healthy volunteers. No dose adjustment is required.<br />The most potent of the CYP3A4 inhibitors such as ketoconazole and itraconazole would be expected<br />to have effects similar to ritonavir (see section 4.3). CYP3A4 inhibitors like clarithromycin, telithromycin and nefazodone are expected to have an effect in between that of ritonavir and CYP3A4 inhibitors like saquinavir or erythromycin, a seven-fold increase in exposure is assumed. Therefore dose adjustments are recommended when using CYP3A4 inhibitors (see section 4.2).<br />The population pharmacokinetic analysis in pulmonary arterial hypertension patients suggested that co-administration of beta-blockers in combination with CYP3A4 substrates might result in an additional increase in sildenafil exposure compared with administration of CYP3A4 substrates alone.<br />Grapefruit juice is a weak inhibitor of CYP3A4 gut wall metabolism and may give rise to modest increases in plasma levels of sildenafil. No dose adjustment is required but the concomitant use of sildenafil and grapefruit juice is not recommended.<br />Single doses of antacid (magnesium hydroxide/aluminium hydroxide) did not affect the bioavailability of sildenafil.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Co-administration of oral contraceptives (ethinyloestradiol 30 g and levonorgestrel 150 g) did not affect the pharmacokinetics of sildenafil.<br />Nicorandil is a hybrid of potassium channel activator and nitrate. Due to the nitrate component it has the potential to have serious interaction with sildenafil (see section 4.3).<br />Effects of sildenafil on other medicinal products<br />In vitro studies<br />Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4<br />(IC50 &gt; 150 M).<br />There are no data on the interaction of sildenafil and non-specific phosphodiesterase inhibitors such<br />as theophylline or dipyridamole.<br />In vivo studies<br />No significant interactions were shown when sildenafil (50 mg) was co-administered with tolbutamide (250 mg) or warfarin (40 mg), both of which are metabolised by CYP2C9.<br />Sildenafil had no significant effect on atorvastatin exposure (AUC increased 11 %), suggesting that sildenafil does not have a clinically relevant effect on CYP3A4.<br />No interactions were observed between sildenafil (100 mg single dose) and acenocoumarol.<br />Sildenafil (50 mg) did not potentiate the increase in bleeding time caused by acetyl salicylic acid (150 mg).<br />Sildenafil (50 mg) did not potentiate the hypotensive effects of alcohol in healthy volunteers with<br />mean maximum blood alcohol levels of 80 mg/dl.<br />In a study of healthy volunteers sildenafil at steady state (80 mg three times a day) resulted in a 50 % increase in bosentan AUC (125 mg twice daily). A population pharmacokinetic analysis of data from a study of adult PAH patients on background bosentan therapy (62.5 mg - 125 mg twice a day) indicated an increase (20% (95% CI: 9.8 - 30.8)) of bosentan AUC with co-administration of steadystate sildenafil (20 mg three times a day) of a smaller magnitude than seen in healthy volunteers when co-administered with 80 mg sildenafil three times a day (see sections 4.4 and 5.1).<br />In a specific interaction study, where sildenafil (100 mg) was co-administered with amlodipine in hypertensive patients, there was an additional reduction on supine systolic blood pressure of 8 mmHg.<br />The corresponding additional reduction in supine diastolic blood pressure was 7 mmHg. These additional blood pressure reductions were of a similar magnitude to those seen when sildenafil was administered alone to healthy volunteers.<br />In three specific drug-drug interaction studies, the alpha-blocker doxazosin (4 mg and 8 mg) and sildenafil (25 mg, 50 mg, or 100 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy. In these study populations, mean additional reductions of supine systolic and diastolic blood pressure of 7/7 mmHg, 9/5 mmHg, and<br />8/4 mmHg, respectively, and mean additional reductions of standing blood pressure of 6/6 mmHg,<br />11/4 mmHg, and 4/5 mmHg, respectively were observed. When sildenafil and doxazosin were administered simultaneously to patients stabilized on doxazosin therapy, there were infrequent reports of patients who experienced symptomatic postural hypotension. These reports included dizziness and<br />lightheadedness, but not syncope. Concomitant administration of sildenafil to patients taking alpha-blocker therapy may lead to symptomatic hypotension in susceptible individuals (see section<br />4.4).<br />Sildenafil (100 mg single dose) did not affect the steady state pharmacokinetics of the HIV protease inhibitor saquinavir, which is a CYP3A4 substrate/inhibitor.<br />Consistent with its known effects on the nitric oxide/cGMP pathway (see section 5.1), sildenafil was shown to potentiate the hypotensive effects of nitrates, and its co-administration with nitric oxide donors or nitrates in any form is therefore contraindicated (see section 4.3).<br />Riociguat: Preclinical studies showed additive systemic blood pressure lowering effect when PDE5 inhibitors were combined with riociguat. In clinical studies, riociguat has been shown to augment the hypotensive effects of PDE5 inhibitors. There was no evidence of favourable clinical effect of the combination in the population studied. Concomitant use of riociguat with PDE5 inhibitors, including sildenafil, is contraindicated (see section 4.3).<br />Sildenafil had no clinically significant impact on the plasma levels of oral contraceptives (ethinyloestradiol 30 g and levonorgestrel 150 g).<br />Paediatric population<br />Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Women of childbearing potential and contraception in males and females<br />Due to lack of data on effects of Sildenafil in pregnant women, Sildenafil OHRE Pharma is not recommended for women of childbearing potential unless also using appropriate contraceptive measures.<br />Pregnancy<br />There are no data from the use of sildenafil in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy and embryonal/foetal development. Studies in animals have shown toxicity with respect to postnatal development (see section 5.3).<br />Due to lack of data, Sildenafil OHRE Pharma should not be used in pregnant women unless strictly necessary.<br />Breast-feeding<br />It is not known whether sildenafil enters the breast milk. Sildenafil OHRE Pharma should not be administered to breast-feeding mothers.<br />Fertility<br />Non-clinical data revealed no special hazard for humans based on conventional studies of fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Sildenafil OHRE Pharma has moderate influence on the ability to drive and use machines.<br />As dizziness and altered vision were reported in clinical trials with sildenafil, patients should be aware of how they might be affected by Sildenafil OHRE Pharma, before driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Summary of the safety profile<br />In the pivotal placebo-controlled study of Sildenafil in pulmonary arterial hypertension, a total of 207 patients were randomized to and treated with 20 mg, 40 mg, or 80 mg TID doses of Sildenafil and 70 patients were randomized to placebo. The duration of treatment was 12 weeks. The overall frequency of discontinuation in sildenafil treated patients at doses of 20 mg, 40 mg and 80 mg TID was 2.9 %, 3.0 % and 8.5 % respectively, compared to 2.9 % with placebo. Of the 277 subjects treated in the pivotal study, 259 entered a long-term extension study. Doses up to 80 mg three times a day (4 times the recommended dose of 20 mg three times a day) were administered and after 3 years 87 % of 183 patients on study treatment were receiving Sildenafil 80 mg TID.<br />In a placebo-controlled study of Sildenafil as an adjunct to intravenous epoprostenol in pulmonary arterial hypertension, a total of 134 patients were treated with Sildenafil (in a fixed titration starting from 20 mg, to 40 mg and then 80 mg, three times a day, as tolerated) and epoprostenol, and 131 patients were treated with placebo and epoprostenol. The duration of treatment was 16 weeks.<br />The overall frequency of discontinuations in sildenafil/epoprostenol treated patients due to adverse events was 5.2 % compared to 10.7 % in the placebo/epoprostenol treated patients. Newly reported adverse reactions, which occurred more frequently in the sildenafil/ epoprostenol group, were ocular hyperaemia, vision blurred, nasal congestion, night sweats, back pain and dry mouth. The known adverse reactions headache, flushing, pain in extremity and oedema were noted in a higher frequency in sildenafil/epoprostenol treated patients compared to placebo/epoprostenol treated patients. Of the subjects who completed the initial study, 242 entered a long-term extension study. Doses up to 80 mg<br />TID were administered and after 3 years 68 % of 133 patients on study treatment were receiving Sildenafil 80 mg TID.<br />In the twoplacebo-controlled studies adverse events were generally mild to moderate in severity. The most commonly reported adverse reactions that occurred (greater or equal to 10 %) on Sildenafil compared to placebo were headache, flushing, dyspepsia, diarrhoea and pain in extremity.<br />Tabulated list of adverse reactions<br />Adverse reactions which occurred in &gt; 1 % of Sildenafil -treated patients and were more frequent (&gt; 1 % difference) on Sildenafil in the pivotal study or in the Sildenafil combined data set of both the placebo-controlled studies in pulmonary arterial hypertension, at doses of 20, 40 or 80 mg TID are listed in the table below by class and frequency grouping (very common (1/10), common (1/100 to &lt; 1/10), uncommon (1/1000 to &lt; 1/100) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.<br />Reports from post-marketing experience are included in italics.<br />MedDRA system organ class (V.14.0)<br />Adverse reaction<br />Infections and infestations<br />Common<br />cellulitis, influenza, bronchitis,<br />sinusitis, rhinitis, gastroenteritis<br />Blood and lymphatic system disorders<br />Common<br />anaemia<br />Metabolism and nutrition disorders Common<br />fluid retention<br />Psychiatric disorders<br />Common<br />insomnia, anxiety<br />Nervous system disorders<br />Very common<br />Common<br />headache<br />migraine, tremor, paraesthesia, burning sensation, hypoaesthesia<br />Eye disorders<br />Common<br />Uncommon<br />Not known<br />retinal haemorrhage, visual impairment, vision blurred, photophobia, chromatopsia, cyanopsia, eye irritation, ocular hyperaemia<br />visual acuity reduced, diplopia,abnormal sensation in eye<br />Non-arteritic anterior ischaemic optic neuropathy (NAION)*, Retinal vascular occlusion*, Visual field defect*<br />Ear and labyrinth disorders<br />Common<br />Not known<br />vertigo<br />sudden hearing loss<br />Vascular disorders<br />Very common<br />Not Known<br />flushing<br />hypotension<br />Respiratory, thoracic and mediastinal disorders<br />Common<br />epistaxis, cough, nasal congestion<br />Gastrointestinal disorders<br />Very common<br />Common<br />diarrhoea, dyspepsia<br />gastritis, gastrooesophageal reflux<br />disease, haemorrhoids, abdominal<br />distension, dry mouth<br />Skin and subcutaneous tissue disorders<br />Common<br />Not known<br />alopecia, erythema, night sweats<br />rash<br />Musculoskeletal and connective tissue disorders<br />Very common<br />Common<br />pain in extremity<br />myalgia, back pain<br />Renal and urinary disorders<br />Uncommon<br />haematuria<br />Reproductive system and breast disorders<br />Uncommon<br />Not known<br />penile haemorrhage, haematospermia, gynaecomastia<br />priapism, erection increased<br />General disorders and administration site conditions<br />Common<br />pyrexia<br />*These adverse events/reactions have been reported in patients taking sildenafil for the treatment of male erectile dysfunction (MED).<br />Paediatric population<br />In the placebo-controlled study of Sildenafil in patients 1 to 17 years of age with pulmonary arterial hypertension, a total of 174 patients were treated three times a day with either low (10 mg in patients<br />&gt; 20 kg; no patients &le; 20 kg received the low dose), medium (10 mg in patients &ge; 8-20 kg; 20 mg in patients &ge; 20-45 kg; 40 mg in patients &gt; 45 kg) or high dose (20 mg in patients &ge; 8-20 kg; 40 mg in patients &ge; 20-45 kg; 80 mg in patients &gt; 45 kg) regimens of Sildenafil and 60 were treated with placebo.<br />The adverse reactions profile seen in this paediatric study was generally consistent with that in adults (see table above). The most common adverse reactions that occurred (with a frequency &ge; 1 %) in<br />Sildenafil patients (combined doses) and with a frequency &gt; 1 % over placebo patients were pyrexia, upper respiratory tract infection (each 11.5%), vomiting (10.9%), erection increased (including spontaneous penile erections in male subjects) (9.0%), nausea, bronchitis (each 4.6%), pharyngitis (4.0%), rhinorrhoea (3.4%), and pneumonia, rhinitis (each 2.9%).<br />Of the 234 paediatric subjects treated in the short-term, placebo-controlled study, 220 subjects entered the long-term extension study. Subjects on active sildenafil therapy continued on the same treatment regimen, while those in the placebo group in the short-term study were randomly reassigned to sildenafil treatment.<br />The most common adverse reactions reported across the duration of the short-term and long-term studies were generally similar to those observed in the short-term study. Adverse reactions reported in &gt;10% of 229 subjects treated with sildenafil (combined dose group, including 9 patients that did not continue into the long-term study) were upper respiratory infection (31%), headache (26%), vomiting (22%), bronchitis (20%), pharyngitis (18%), pyrexia (17%), diarrhoea (15%), and influenza, epistaxis (12% each). Most of these adverse reactions were considered mild to moderate in severity.<br />Serious adverse events were reported in 94 (41%) of the 229 subjects receiving sildenafil. Of the 94 subjects reporting a serious adverse event, 14/55 (25.5%) subjects were in the low dose group, 35/74<br />(47.3%) in the medium dose group, and 45/100 (45%) in the high dose group. The most common serious adverse events that occurred with a frequency &ge; 1 % in sildenafil patients (combined doses) were pneumonia (7.4%), cardiac failure, pulmonary hypertension (each 5.2%), upper respiratory tract infection (3.1%), right ventricular failure, gastroenteritis (each 2.6%), syncope, bronchitis, bronchopneumonia, pulmonary arterial hypertension (each 2.2%), chest pain, dental caries (each 1.7%), and cardiogenic shock, gastroenteritis viral, urinary tract infection (each 1.3%).<br />The following serious adverse events were considered to be treatment related, enterocolitis, convulsion, hypersensitivity, stridor, hypoxia, neurosensory deafness and ventricular arrhythmia.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">In single dose volunteer studies of doses up to 800 mg, adverse reactions were similar to those seen at lower doses, but the incidence rates and severities were increased. At single doses of 200 mg the incidence of adverse reactions (headache, flushing, dizziness, dyspepsia, nasal congestion, and altered vision) was increased.<br />In cases of overdose, standard supportive measures should be adopted as required. Renal dialysis is not expected to accelerate clearance as sildenafil is highly bound to plasma proteins and not eliminated in the urine.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmacotherapeutic group: Urologicals, Drugs used in erectile dysfunction, ATC code: G04BE03<br />Mechanism of action<br />Sildenafil is a potent and selective inhibitor of cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 (PDE5), the enzyme that is responsible for degradation of cGMP. Apart from the presence of this enzyme in the corpus cavernosum of the penis, PDE5 is also present in the pulmonary vasculature. Sildenafil, therefore, increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation. In patients with pulmonary arterial hypertension this can lead to vasodilation of the pulmonary vascular bed and, to a lesser degree, vasodilatation in the systemic circulation.<br />Pharmacodynamic effects<br />Studies in vitro have shown that sildenafil is selective for PDE5. Its effect is more potent on PDE5 than on other known phosphodiesterases. There is a 10-fold selectivity over PDE6 which is involved in the phototransduction pathway in the retina. There is an 80-fold selectivity over PDE1, and over 700-fold over PDE 2, 3, 4, 7, 8, 9, 10 and 11. In particular, sildenafil has greater than 4,000-fold selectivity for PDE5 over PDE3, the cAMP-specific phosphodiesterase isoform involved in the control of cardiac contractility.<br />Sildenafil causes mild and transient decreases in systemic blood pressure which, in the majority of cases, do not translate into clinical effects. After chronic dosing of 80 mg three times a day to patients with systemic hypertension the mean change from baseline in systolic and diastolic blood pressure was a decrease of 9.4 mmHg and 9.1 mm Hg respectively. After chronic dosing of 80 mg three times a day to patients with pulmonary arterial hypertension lesser effects in blood pressure reduction were observed (a reduction in both systolic and diastolic pressure of 2 mmHg). At the recommended dose of 20 mg three times a day no reductions in systolic or diastolic pressure were seen.<br />Single oral doses of sildenafil up to 100 mg in healthy volunteers produced no clinically relevant effects on ECG. After chronic dosing of 80 mg three times a day to patients with pulmonary arterial hypertension no clinically relevant effects on the ECG were reported.<br />In a study of the hemodynamic effects of a single oral 100 mg dose of sildenafil in 14 patients with severe coronary artery disease (CAD) (&gt; 70 % stenosis of at least one coronary artery), the mean resting systolic and diastolic blood pressures decreased by 7 % and 6 % respectively compared to baseline. Mean pulmonary systolic blood pressure decreased by 9 %. Sildenafil showed no effect on cardiac output, and did not impair blood flow through the stenosed coronary arteries.<br />Mild and transient differences in colour discrimination (blue/green) were detected in some subjects using the Farnsworth-Munsell 100 hue test at 1 hour following a 100 mg dose, with no effects evident after 2 hours post-dose. The postulated mechanism for this change in colour discrimination is related to<br />inhibition of PDE6, which is involved in the phototransduction cascade of the retina. Sildenafil has no effect on visual acuity or contrast sensitivity. In a small size placebo-controlled study of patients with documented early age-related macular degeneration (n = 9), sildenafil (single dose, 100 mg) demonstrated no significant changes in visual tests conducted (visual acuity, Amsler grid, colour discrimination simulated traffic light, Humphrey perimeter and photostress).<br />Clinical efficacy and safety<br />Efficacy in adult patients with pulmonary arterial hypertension (PAH)<br />A randomised, double-blind, placebo-controlled study was conducted in 278 patients with primary pulmonary hypertension, PAH associated with connective tissue disease, and PAH following surgical repair of congenital heart lesions. Patients were randomised to one of four treatment groups: placebo,<br />sildenafil 20 mg, sildenafil 40 mg or sildenafil 80 mg, three times a day. Of the 278 patients randomised, 277 patients received at least 1 dose of study drug. The study population consisted of<br />68 (25 %) men and 209 (75 %) women with a mean age of 49 years (range: 18-81 years) and baseline<br />6-minute walk test distance between 100 and 450 metres inclusive (mean: 344 metres). 175 patients (63 %) included were diagnosed with primary pulmonary hypertension, 84 (30 %) were diagnosed with PAH associated with connective tissue disease and 18 (7 %) of the patients were diagnosed with<br />PAH following surgical repair of congenital heart lesions. Most patients were WHO Functional Class<br />II (107/277, 39 %) or III (160/277, 58 %) with a mean baseline 6 minute walking distance of<br />378 meters and 326 meters respectively; fewer patients were Class I (1/277, 0.4 %) or IV (9/277, 3 %) at baseline. Patients with left ventricular ejection fraction &lt; 45 % or left ventricular shortening fraction &lt; 0.2 were not studied.<br />Sildenafil (or placebo) was added to patients&rsquo; background therapy which could have included a combination of anticoagulation, digoxin, calcium channel blockers, diuretics or oxygen. The use of prostacyclin, prostacyclin analogues and endothelin receptor antagonists was not permitted as add-on therapy, and neither was arginine supplementation. Patients who previously failed bosentan therapy were excluded from the study.<br />The primary efficacy endpoint was the change from baseline at week 12 in 6-minute walk distance<br />(6MWD). A statistically significant increase in 6MWD was observed in all 3 sildenafil dose groups compared to those on placebo. Placebo corrected increases in 6MWD were 45 metres (p &lt; 0.0001),<br />46 metres (p &lt; 0.0001) and 50 metres (p &lt; 0.0001) for sildenafil 20 mg, 40 mg and 80 mg TID respectively. There was no significant difference in effect between sildenafil doses. For patients with a baseline 6MWD &lt; 325 m improved efficacy was observed with higher doses (placebo-corrected improvements of 58 metres, 65 metres and 87 metres for 20 mg, 40 mg and 80 mg doses TID, respectively).<br />When analysed by WHO functional class, a statistically significant increase in 6MWD was observed in the 20 mg dose group. For class II and class III, placebo corrected increases of 49 metres<br />(p = 0.0007) and 45 metres (p = 0.0031) were observed respectively.<br />The improvement in 6MWD was apparent after 4 weeks of treatment and this effect was maintained at weeks 8 and 12. Results were generally consistent in subgroups according to aetiology (primary and connective tissue disease-associated PAH), WHO functional class, gender, race, location, mean PAP and PVRI.<br />Patients on all sildenafil doses achieved a statistically significant reduction in mean pulmonary arterial pressure (mPAP) and pulmonary vascular resistance (PVR) compared to those on placebo.<br />Placebo-corrected treatment effects with mPAP were &ndash;2.7 mmHg (p = 0.04), -3.0 mm Hg (p = 0.01)<br />and -5.1 mm Hg (p &lt; 0.0001) for sildenafil 20 mg, 40 mg and 80 mg TID respectively.<br />Placebo-corrected treatment effects with PVR were -178 dyne.sec/cm5 (p=0.0051), -195 dyne.sec/cm5<br />(p=0.0017) and -320 dyne.sec/cm5 (p&lt;0.0001) for sildenafil 20 mg, 40 mg and 80 mg TID, respectively. The percent reduction at 12 weeks for sildenafil 20 mg, 40 mg and 80 mg TID in PVR (11.2 %, 12.9 %, 23.3 %) was proportionally greater than the reduction in systemic vascular resistance (SVR) (7.2 %, 5.9<br />%, 14.4 %). The effect of sildenafil on mortality is unknown. A greater percentage of patients on each of the sildenafil doses (i.e. 28 %, 36 % and 42 % of subjects who received sildenafil 20 mg, 40 mg and 80 mg TID doses, respectively) showed an improvement by at least one WHO functional class at week 12 compared to placebo (7 %). The respective odds ratios were 2.92 (p=0.0087), 4.32 (p=0.0004) and 5.75 (p&lt;0.0001).<br />Long-term survival data in naive population<br />Patients enrolled into the pivotal study were eligible to enter a long term open label extension study.<br />At 3 years 87 % of the patients were receiving a dose of 80 mg TID. A total of 207 patients were treated with Sildenafil OHRE Pharma in the pivotal study, and their long term survival status was assessed for a minimum of 3 years. In this population, Kaplan-Meier estimates of 1, 2 and 3 year survival were 96 %, 91 % and 82 %, respectively. Survival in patients of WHO functional class II at baseline at 1, 2 and 3 years was 99 %, 91 %, and 84 % respectively, and for patients of WHO functional class III at baseline was 94 %, 90 %, and 81 %, respectively.<br />Efficacy in adult patients with PAH (when used in combination with epoprostenol)<br />A randomised, double-blind, placebo controlled study was conducted in 267 patients with PAH who were stabilised on intravenous epoprostenol. The PAH patients included those with Primary<br />Pulmonary Arterial Hypertension (212/267, 79 %) and PAH associated with connective tissue disease (55/267, 21 %). Most patients were WHO Functional Class II (68/267, 26 %) or III (175/267, 66 %); fewer patients were Class I (3/267, 1 %) or IV (16/267, 6 %) at baseline; for a few patients (5/267,<br />2 %), the WHO Functional Class was unknown. Patients were randomised to placebo or sildenafil (in a fixed titration starting from 20 mg, to 40 mg and then 80 mg, three times a day as tolerated) when used in combination with intravenous epoprostenol.<br />The primary efficacy endpoint was the change from baseline at week 16 in 6-minute walk distance.<br />There was a statistically significant benefit of sildenafil compared to placebo in 6-minute walk distance. A mean placebo corrected increase in walk distance of 26 metres was observed in favour of sildenafil (95 % CI: 10.8, 41.2) (p = 0.0009). For patients with a baseline walking distance<br />&ge; 325 metres, the treatment effect was 38.4 metres in favour of sildenafil; for patients with a baseline walking distance &lt; 325 metres, the treatment effect was 2.3 metres in favour of placebo. For patients with primary PAH, the treatment effect was 31.1 metres compared to 7.7 metres for patients with PAH associated with connective tissue disease. The difference in results between these randomization subgroups may have arisen by chance in view of their limited sample size.<br />Patients on sildenafil achieved a statistically significant reduction in mean Pulmonary Arterial Pressure (mPAP) compared to those on placebo. A mean placebo-corrected treatment effect of -3.9 mmHg was observed in favour of sildenafil (95 % CI: -5.7, -2.1) (p = 0.00003). Time to clinical worsening was a secondary endpoint as defined as the time from randomisation to the first occurrence of a clinical worsening event (death, lung transplantation, initiation of bosentan therapy, or clinical deterioration requiring a change in epoprostenol therapy). Treatment with sildenafil significantly delayed the time to clinical worsening of PAH compared to placebo (p = 0.0074). 23 subjects experienced clinical worsening events in the placebo group (17.6 %) compared with 8 subjects in the sildenafil group (6.0 %).<br />Long-term Survival Data in the background epoprostenol study<br />Patients enrolled into the epoprostenol add-on therapy study were eligible to enter a long term open label extension study. At 3 years 68 % of the patients were receiving a dose of 80 mg TID. A total of 134 patients were treated with Sildenafil OHRE Pharma in the initial study, and their long term survival status was assessed for a minimum of 3 years. In this population, Kaplan-Meier estimates of 1, 2 and 3 year survival were 92 %, 81 % and 74 %, respectively.<br />Efficacy and safety in adult patients with PAH (when used in combination with bosentan)<br />A randomized, double-blind, placebo controlled study was conducted in 103 clinically stable subjects with PAH (WHO FC II and III) who were on bosentan therapy for a minimum of three months. The<br />PAH patients included those with primary PAH, and PAH associated with connective tissue disease.<br />Patients were randomized to placebo or sildenafil (20 mg three times a day) in combination with bosentan (62.5-125 mg twice a day). The primary efficacy endpoint was the change from baseline at Week 12 in 6MWD. The results indicate that there is no significant difference in mean change from baseline on 6MWD observed between sildenafil (20 mg three times a day) and placebo (13.62 m (95% CI: -3.89 to 31.12) and 14.08 m (95% CI: -1.78 to 29.95), respectively).<br />Differences in 6MWD were observed between patients with primary PAH and PAH associated with connective tissue disease. For subjects with primary PAH (67 subjects), mean changes from baseline were 26.39 m (95% CI: 10.70 to 42.08) and 11.84 m (95% CI: -8.83 to 32.52) for the sildenafil and placebo groups, respectively. However, for subjects with PAH associated with connective tissue disease (36 subjects) mean changes from baseline were -18.32 m (95% CI: -65.66 to 29.02) and 17.50 m (95% CI: -9.41 to 44.41) for the sildenafil and placebo groups, respectively.<br />Overall, the adverse events were generally similar between the two treatment groups (sildenafil plus bosentan vs. bosentan alone), and consistent with the known safety profile of sildenafil when used as monotherapy (see sections 4.4 and 4.5).<br />Paediatric population<br />A total of 234 subjects aged 1 to 17 years were treated in a randomized, double-blind, multi-centre, placebo controlled parallel group, dose ranging study. Subjects (38 % male and 62 % female) had a body weight 8 kg, and had primary pulmonary hypertension (PPH) [33 %], or PAH secondary to congenital heart disease [systemic-to-pulmonary shunt 37 %, surgical repair 30 %]. In this trial, 63 of<br />234 (27 %) patients were &lt; 7 years old (sildenafil low dose = 2; medium dose = 17; high dose = 28; placebo = 16) and 171 of 234 (73 %) patients were 7 years or older (sildenafil low dose = 40; medium dose = 38; and high dose = 49; placebo = 44). Most subjects were WHO Functional Class I (75/234,<br />32 %) or II (120/234, 51 %) at baseline; fewer patients were Class III (35/234, 15 %) or IV (1/234,<br />0.4 %); for a few patients (3/234, 1.3 %), the WHO Functional Class was unknown.<br />Patients were na&iuml;ve for specific PAH therapy and the use of prostacyclin, prostacyclin analogues and endothelin receptor antagonists was not permitted in the study, and neither was arginine supplementation, nitrates, alpha-blockers and potent CYP450 3A4 inhibitors.<br />The primary objective of the study was to assess the efficacy of 16 weeks of chronic treatment with oral sildenafil in paediatric subjects to improve exercise capacity as measured by the<br />Cardiopulmonary Exercise Test (CPET) in subjects who were developmentally able to perform the test, n = 115). Secondary endpoints included haemodynamic monitoring, symptom assessment, WHO functional class, change in background treatment, and quality of life measurements.<br />Subjects were allocated to one of three sildenafil treatment groups, low (10 mg), medium (10-40 mg) or high dose (20-80 mg) regimens of Sildenafil OHRE Pharma given three times a day, or placebo. Actual doses administered within a group were dependent on body weight (see Section 4.8). The proportion of subjects receiving supportive medicinal products at baseline (anticoagulants, digoxin, calcium channel blockers, diuretics and/or oxygen) was similar in the combined sildenafil treatment group (47.7 %) and the placebo treatment group (41.7 %).<br />The primary endpoint was the placebo-corrected percentage change in peak VO2 from baseline to week 16 assessed by CPET testing in the combined dose groups (Table 2). A total of 106 out of 234 (45 %) subjects were evaluable for CPET, which comprised those children &ge; 7 years old and developmentally able to perform the test. Children &lt; 7 years (sildenafil combined dose = 47; placebo<br />= 16) were evaluable only for the secondary endpoints. Mean baseline peak volume of oxygen consumed (VO2) values were comparable across the sildenafil treatment groups (17.37 to 18.03 ml/kg/min), and slightly higher for the placebo treatment group (20.02 ml/kg/min). The results of the main analysis (combined dose groups versus placebo) were not statistically significant (p = 0.056) (see<br />Table 2). The estimated difference between the medium sildenafil dose and placebo was 11.33 % (95 % CI: 1.72 to 20.94) (see Table 2).<br />Table 2: Placebo Corrected % Change from Baseline in Peak VO2 by Active Treatment Group<br />Treatment group<br />Estimated difference<br />95% confidence interval<br />Low dose<br />(n=24)<br />3.81<br />-6.11, 13.73<br />Medium dose<br />(n=26)<br />11.33<br />1.72, 20.94<br />High dose<br />(n=27)<br />7.98<br />-1.64, 17.60<br />Combined dose groups<br />(n=77)<br />7.71<br />(p = 0.056)<br />-0.19, 15.60<br />n=29 for placebo group<br />Estimates based on ANCOVA with adjustments for the covariates baseline peak VO2, etiology and weight group<br />Dose related improvements were observed with pulmonary vascular resistance index (PVRI) and mean pulmonary arterial pressure (mPAP). The sildenafil medium and high dose groups both showed<br />PVRI reductions compared to placebo, of 18 % (95 % CI: 2 % to 32 %) and 27 % (95 % CI: 14 % to 39 %), respectively; whilst the low dose group showed no significant difference from placebo (difference of 2 %). The sildenafil medium and high dose groups displayed mPAP changes from baseline compared to placebo, of -3.5 mmHg (95 % CI: -8.9, 1.9) and -7.3 mmHg (95 % CI: -12.4, -2.1), respectively; whilst the low dose group showed little difference from placebo (difference of 1.6 mmHg). Improvements were observed with cardiac index with all three sildenafil groups over placebo, 10 %, 4 % and 15 % for the low, medium and high dose groups respectively.<br />Significant improvements in functional class were demonstrated only in subjects on sildenafil high dose compared to placebo. Odds ratios for the sildenafil low, medium and high dose groups compared to placebo were 0.6 (95 % CI: 0.18, 2.01), 2.25 (95 % CI: 0.75, 6.69) and 4.52 (95 % CI: 1.56, 13.10), respectively.<br />Long term extension data<br />Of the 234 paediatric subjects treated in the short-term, placebo-controlled study, 220 subjects entered the long-term extension study. Subjects who had been in the placebo group in the short-term study were randomly reassigned to sildenafil treatment; subjects weighing &le; 20 kg entered the medium or high dose groups (1:1), while subjects weighing &gt; 20 kg entered the low, medium or high dose groups<br />(1:1:1). Of the total 229 subjects who received sildenafil, there were 55, 74, and 100 subjects in the low, medium and high dose groups, respectively. Across the short-term and long-term studies, the overall duration of treatment from start of double-blind for individual subjects ranged from 3 to 3129 days. By sildenafil treatment group, median duration of sildenafil treatment was 1696 days (excluding the 5 subjects who received placebo in double-blind and were not treated in the long-term extension study).<br />Kaplan-Meier estimates of survival at 3 years in patients &gt; 20 kg in weight at baseline were 94 %, 93 % and 85 % in the low, medium and high dose groups, respectively; for patients &le; 20 kg in weight at baseline, the survival estimates were 94 % and 93 % for subjects in the medium and high dose groups respectively (see sections 4.4 and 4.8).<br />During the conduct of the study, there were a total of 42 deaths reported, whether on treatment or reported as part of the survival follow-up. 37 deaths occurred prior to a decision taken by the Data<br />Monitoring Committee to down titrate subjects to a lower dosage, based on an observed mortality imbalance with increasing sildenafil doses. Among these 37 deaths, the number (%) of deaths was<br />5/55 (9.1%), 10/74 (13.5%), and 22/100 (22%) in the sildenafil low, medium, and high dose groups, respectively. An additional 5 deaths were reported subsequently.The causes of deaths were related to<br />PAH. Higher than recommended doses should not be used in paediatric patients with PAH (see sections 4.2 and 4.4).<br />Peak VO2 was assessed 1 year after the start of the placebo-controlled study. Of those sildenafil treated subjects developmentally able to perform the CPET 59/114 subjects (52 %) had not shown any deterioration in Peak VO2 from start of sildenafil. Similarly 191 of 229 subjects (83 %) who had received sildenafil had either maintained or improved their WHO Functional Class at 1 year assessment.<br />The European Medicines Agency has deferred the obligation to submit the results of studies with Sildenafil in newborns with pulmonary arterial hypertension (see section 4.2 for information on paediatric use).<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Absorption<br />Sildenafil is rapidly absorbed. Maximum observed plasma concentrations are reached within 30 to<br />120 minutes (median 60 minutes) of oral dosing in the fasted state. The mean absolute oral bioavailability is 41 % (range 25-63 %). After oral three times a day dosing of sildenafil, AUC and Cmax increase in proportion with dose over the dose range of 20-40 mg. After oral doses of 80 mg three times a day a more than dose proportional increase in sildenafil plasma levels has been observed. In pulmonary arterial hypertension patients, the oral bioavailability of sildenafil after 80 mg three times a day was on average 43 % (90 % CI: 27 % - 60 %) higher compared to the lower doses.<br />When sildenafil is taken with food, the rate of absorption is reduced with a mean delay in Tmax of<br />60 minutes and a mean reduction in Cmax of 29 % however, the extent of absorption was not significantly affected (AUC decreased by 11 %).<br />Distribution<br />The mean steady state volume of distribution (Vss) for sildenafil is 105 l, indicating distribution into the tissues. After oral doses of 20 mg three times a day, the mean maximum total plasma concentration of sildenafil at steady state is approximately 113 ng/ml. Sildenafil and its major circulating N-desmethyl metabolite are approximately 96 % bound to plasma proteins. Protein binding is independent of total drug concentrations.<br />Biotransformation<br />Sildenafil is cleared predominantly by the CYP3A4 (major route) and CYP2C9 (minor route) hepatic microsomal isoenzymes. The major circulating metabolite results from N-demethylation of sildenafil.<br />This metabolite has a phosphodiesterase selectivity profile similar to sildenafil and an in vitro potency for PDE5 approximately 50 % that of the parent drug. The N-desmethyl metabolite is further metabolised, with a terminal half-life of approximately 4 h. In patients with pulmonary arterial hypertension, plasma concentrations of N-desmethyl metabolite are approximately 72 % those of sildenafil after 20 mg three<br />times a day dosing (translating into a 36 % contribution to sildenafil&rsquo;s pharmacological effects). The subsequent effect on efficacy is unknown.<br />Elimination<br />The total body clearance of sildenafil is 41 l/h with a resultant terminal phase half-life of 3-5 h. After either oral or intravenous administration, sildenafil is excreted as metabolites predominantly in the faeces (approximately 80 % of administered oral dose) and to a lesser extent in the urine (approximately 13 % of administered oral dose).<br />Pharmacokinetics in special patient groups<br />Elderly<br />Healthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil, resulting in approximately 90 % higher plasma concentrations of sildenafil and the active N-desmethyl metabolite compared to those seen in healthy younger volunteers (18-45 years). Due to age-differences in plasma protein binding, the corresponding increase in free sildenafil plasma concentration was approximately<br />40 %.<br />Renal insufficiency<br />In volunteers with mild to moderate renal impairment (creatinine clearance = 30-80 ml/min), the pharmacokinetics of sildenafil were not altered after receiving a 50 mg single oral dose. In volunteers with severe renal impairment (creatinine clearance &lt; 30 ml/min), sildenafil clearance was reduced, resulting in mean increases in AUC and Cmax of 100 % and 88 % respectively compared to age-matched volunteers with no renal impairment. In addition, N-desmethyl metabolite AUC and Cmax values were significantly increased by 200 % and 79 % respectively in subjects with severe renal impairment compared to subjects with normal renal function.<br />Hepatic insufficiency<br />In volunteers with mild to moderate hepatic cirrhosis (Child-Pugh class A and B) sildenafil clearance was reduced, resulting in increases in AUC (85 %) and Cmax (47 %) compared to age-matched volunteers with no hepatic impairment. In addition, N-desmethyl metabolite AUC and Cmax values were significantly increased by 154 % and 87 %, respectively in cirrhotic subjects compared to subjects with normal hepatic function. The pharmacokinetics of sildenafil in patients with severely impaired hepatic function have not been studied.<br />Population pharmacokinetics<br />In patients with pulmonary arterial hypertension, the average steady state concentrations were<br />20-50 % higher over the investigated dose range of 20&ndash;80 mg three times a day compared to healthy volunteers. There was a doubling of the Cmin compared to healthy volunteers. Both findings suggest a lower clearance and/or a higher oral bioavailability of sildenafil in patients with pulmonary arterial hypertension compared to healthy volunteers.<br />Paediatric population<br />From the analysis of the pharmacokinetic profile of sildenafil in patients involved in the paediatric clinical trials, body weight was shown to be a good predictor of drug exposure in children. Sildenafil plasma concentration half-life values were estimated to range from 4.2 to 4.4 hours for a range of 10 to 70 kg of body weight and did not show any differences that would appear as clinically relevant.<br />Cmax after a single 20 mg sildenafil dose administered PO was estimated at 49, 104 and 165 ng/ml for 70, 20 and 10 kg patients, respectively. Cmax after a single 10 mg sildenafil dose administered PO was estimated at 24, 53 and 85 ng/ml for 70, 20 and 10 kg patients, respectively. Tmax was estimated at approximately 1 hour and was almost independent from body weight.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Non-clinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential, toxicity to reproduction and development.<br />In pups of rats which were pre- and postnatally treated with 60 mg/kg sildenafil, a decreased litter size, a lower pup weight on day 1 and a decreased 4-day survival were seen at exposures which were approximately fifty times the expected human exposure at 20 mg three times a day. Effects in non-clinical studies were observed at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use.<br />There were no adverse reactions, with possible relevance to clinical use, seen in animals at clinically relevant exposure levels which were not also observed in clinical studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Tablet core:<br />Mannitol<br />Crospovidone, type A<br />Povidone, K-30<br />Maize starch<br />Sodium laurilsulfate<br />Silica, colloidal anhydrous<br />Magnesium stearate<br />Film coat:<br />Hypromellose type 2910<br />Titanium dioxide (E171)<br />Lactose monohydrate<br />Macrogol, type 3350<br />Triacetin</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets: 3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">No special precautions for storage</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">PVC/Aluminium blisters of 90 tablets.<br />Pack size of 90 tablets in a carton.<br />PVC/Aluminium blisters of 300 tablets.<br />Pack size of 300 tablets in a carton.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">No special requirements for disposal</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                STRAGEN FRANCE
30 rue Edouard Nieuport
69008 Lyon
France
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01/10/2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>